Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis
Interferon (IFN) therapy has an important role in the treatment of multiple sclerosis and chronic hepatitis C infection. A few case reports have described an association between IFN therapy and the development of irreversible pulmonary arterial hypertension (PAH), and it is currently listed as a pos...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2015/181535 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567373339557888 |
|---|---|
| author | E Gibbons S Promislow RA Davies G Chandy DJ Stewart V Contreras-Dominguez C Pugliese R Dunne LM Mielniczuk |
| author_facet | E Gibbons S Promislow RA Davies G Chandy DJ Stewart V Contreras-Dominguez C Pugliese R Dunne LM Mielniczuk |
| author_sort | E Gibbons |
| collection | DOAJ |
| description | Interferon (IFN) therapy has an important role in the treatment of multiple sclerosis and chronic hepatitis C infection. A few case reports have described an association between IFN therapy and the development of irreversible pulmonary arterial hypertension (PAH), and it is currently listed as a possible drug-induced cause of PAH in the most recent classification of pulmonary hypertension. A causal link between IFN use and PAH remains to be elucidated; many reports of PAH resulting from IFN occur in individuals with some other risk factor for PAH. The authors present a case involving a patient with multiple sclerosis with no known risk factors for PAH, who developed severe PAH after exposure to IFN therapy. The patient experienced significant clinical and hemodynamic improvement, with normalization of her pulmonary pressures after the initiation of combination therapy for PAH. At 28 months after diagnosis, she remains asymptomatic with no hemodynamic evidence of PAH and has been off all PAH therapy for 10 months. |
| format | Article |
| id | doaj-art-688fec08800d41f593c9d889ce4a0712 |
| institution | Kabale University |
| issn | 1198-2241 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-688fec08800d41f593c9d889ce4a07122025-02-03T01:01:41ZengWileyCanadian Respiratory Journal1198-22412015-01-0122526326510.1155/2015/181535Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple SclerosisE Gibbons0S Promislow1RA Davies2G Chandy3DJ Stewart4V Contreras-Dominguez5C Pugliese6R Dunne7LM Mielniczuk8University of Ottawa Heart Institute, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaUniversity of Ottawa Heart Institute, Ottawa, Ontario, CanadaInterferon (IFN) therapy has an important role in the treatment of multiple sclerosis and chronic hepatitis C infection. A few case reports have described an association between IFN therapy and the development of irreversible pulmonary arterial hypertension (PAH), and it is currently listed as a possible drug-induced cause of PAH in the most recent classification of pulmonary hypertension. A causal link between IFN use and PAH remains to be elucidated; many reports of PAH resulting from IFN occur in individuals with some other risk factor for PAH. The authors present a case involving a patient with multiple sclerosis with no known risk factors for PAH, who developed severe PAH after exposure to IFN therapy. The patient experienced significant clinical and hemodynamic improvement, with normalization of her pulmonary pressures after the initiation of combination therapy for PAH. At 28 months after diagnosis, she remains asymptomatic with no hemodynamic evidence of PAH and has been off all PAH therapy for 10 months.http://dx.doi.org/10.1155/2015/181535 |
| spellingShingle | E Gibbons S Promislow RA Davies G Chandy DJ Stewart V Contreras-Dominguez C Pugliese R Dunne LM Mielniczuk Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis Canadian Respiratory Journal |
| title | Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis |
| title_full | Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis |
| title_fullStr | Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis |
| title_full_unstemmed | Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis |
| title_short | Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis |
| title_sort | reversible pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis |
| url | http://dx.doi.org/10.1155/2015/181535 |
| work_keys_str_mv | AT egibbons reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis AT spromislow reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis AT radavies reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis AT gchandy reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis AT djstewart reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis AT vcontrerasdominguez reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis AT cpugliese reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis AT rdunne reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis AT lmmielniczuk reversiblepulmonaryarterialhypertensionassociatedwithinterferonbetatreatmentformultiplesclerosis |